The Israeli company had planned raising only $10 million but there was huge demand following its successful Phase II trial on severely ill Covid patients.
Enlivex reports strong Phase II Covid treatment results
14 of the 16 patients taking Alloctera who were severely or critically ill, recovered from Covid-19 and were released from hospital.
Israeli immunotherapy company Enlivex Therapeutics (Nasdaq: ENLV) has reported strong results in its Phase II trial for the efficacy of its drug Alloctera, on patients who are severely or critically ill with Covid-19.
The trial involved 16 patients without a control group, of whom nine were severely ill with Covid-19 and seven were in critical condition. Twenty eight days after the treatment was first administered to the 16 patients, there were no fatalities, and 14 of the 16 patients were released from hospital and returned home. Two patients remain in hospital on ventilators in the intensive care unit. On average, the patients were released from hospital 5.3 days after treatment with Alloctera began.